Top 10 (+ 1) New England Venture Deals of Q3 2009

10/20/09Follow @bbuderi

We’ve brought you a lot of third-quarter venture data in the last week or so—and we’re not done yet (hint: I have something special coming up for you baseball fans). But we haven’t gotten around to our usual Top 10 deals list.

So let me remind you, it was a pretty good quarter here in Massachusetts. Overall venture investment into Bay State startups climbed substantially over Q2, capped by a strong September in which VCs invested some $228 million in 25 deals, according to data from ChubbyBrain, a New York-based information services company.

And now let me show you the list of the top 10 venture deals in New England—all of which happen to be from Massachusetts. This comes from a different set of data provided by Dow Jones VentureSource.

Top 10 New England Venture Deals of the Third Quarter

Epizyme (Cambridge) — $32 million
Second round
(Investors: Amgen Ventures, Astellas Venture Capital, Bay City Capital*, Kleiner Perkins Caufield & Byers, MPM Capital)

Avila Therapeutics (Waltham) — $30 million
Second round
(Investors: Abingworth Management Inc., Advent Venture Partners, Atlas Venture, Novartis Venture Fund*, Polaris Venture Partners)

Gloucester Pharmaceuticals (Cambridge) — $29 million
Later stage
(Investors: Apple Tree Partners, Novo*, ProQuest Investments, Prospect Venture Partners, Rho Ventures)

iWalk (Cambridge) — $20 million
First round
(Investors: General Catalyst Partners*)

Aveo Pharmaceuticals (Cambridge) — $20 million
Corporate financing
(Investors: OSI Pharmaceuticals)

PrimeraDx (Mansfield) — $19.8 million
Later stage
(Investors: Abingworth Management Inc., Burrill & Company, CHL Medical Partners*, InterWest Partners, Invus Group, Malaysia Technology Devt Corp, MPM Capital)

Rapid Micro Biosystems (Bedford) — $18.6 million
First round
(Investors: Kleiner Perkins Caufield & Byers, Quaker BioVentures, TVM Capital GmbH, VIMAC Ventures)

MooBella (Taunton) — $18 million
Later stage
(Investors: Inventages Venture Capital*)

Pervasis Therapeutics (Cambridge) — $17 million
Later stage
(Investors: Flagship Ventures, Highland Capital Partners, Polaris Venture Partners)

Advanced Electron Beams (Wilmington) — $14.3 million
Later stage
(Investors: Atlas Venture, Flagship Ventures*, GE Energy Financial Services, General Catalyst Partners, RockPort Capital Partners)

* Lead investor

I have to mention the 11th ranked deal—iMedX, which took in $13 million in first-round funding. The company hails from Shelton, CT, and was the biggest third-quarter deal in New England outside of Massachusetts.

Bob is Xconomy's founder and editor in chief. You can e-mail him at bbuderi@xconomy.com, call him at 617.500.5926. Follow @bbuderi

By posting a comment, you agree to our terms and conditions.